Cagrilintide Phase 2 trial (NCT03856047)
Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 706
- actual
- Start
- 1 Mar 2019 (actual)
- Primary completion
- 2 Mar 2020 (actual)
- Sponsor
- Novo Nordisk A/S
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NNC0174-0833, 4.5 mg | Experimental | Drug: NNC0174-0833 | Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks. |
| NNC0174-0833, 2.4 mg | Experimental | Drug: NNC0174-0833 | Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks. |
| NNC0174-0833, 1.2 mg | Experimental | Drug: NNC0174-0833 | Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks. |
| NNC0174-0833, 0.6 mg | Experimental | Drug: NNC0174-0833 | Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks. |
| NNC0174-0833 0.3 mg | Experimental | Drug: NNC0174-0833 | Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks. |
| Placebo 2.4 mg (NNC0174-0833) | Placebo comparator | Drug: Placebo (NNC0174-0833) | Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks. |
| Placebo 4.5 mg (NNC0174-0833) | Placebo comparator | Drug: Placebo (NNC0174-0833) | Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks. |
| Placebo 1.2 mg (NNC0174-0833) | Placebo comparator | Drug: Placebo (NNC0174-0833) | Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks. |
| Placebo 0.6 mg (NNC0174-0833) | Placebo comparator | Drug: Placebo (NNC0174-0833) | Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks. |
| Placebo 0.3 mg (NNC0174-0833) | Placebo comparator | Drug: Placebo (NNC0174-0833) | Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks. |
| Liraglutide 3.0 mg | Active comparator | Drug: Liraglutide 3.0 mg | Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks. |
| Placebo 3.0 mg (Liraglutide) | Placebo comparator | Drug: Placebo (Liraglutide 3.0 mg) | Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change in Body Weight (%) | From baseline (week 0) to week 26 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants With Weight Loss of ≥ 5% of Baseline Body Weight at 26 Weeks | Week 26 |
| Percentage of Participants With Weight Loss of ≥ 10% of Baseline Body Weight at 26 Weeks | Week 26 |
| Change in Body Weight (Kg) | From baseline (week 0) to week 26 |
| Change in Waist Circumference | From baseline (week 0) to week 26 |
| Change in Total Cholesterol | From baseline (week 0) to week 26 |
| Change in High Density Lipoprotein (HDL) Cholesterol | From baseline (week 0) to week 26 |
| Change in Low Density Lipoprotein (LDL) Cholesterol | From baseline (week 0) to week 26 |
| Change in Very Low Density Lipoprotein (VLDL) Cholesterol | From baseline (week 0) to week 26 |
| Change in Triglycerides | From baseline (week 0) to week 26 |
| Change in Glycosylated Haemoglobin (HbA1c) (%-Point) | From baseline (week 0) to week 26 |
| Change in HbA1c (mmol/Mol) | From baseline (week 0) to week 26 |
| Change in Fasting Plasma Glucose (FPG) (mmol/L) | From baseline (week 0) to week 26 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT03856047.
Dose-finding design of the cagrilintide weight-management trial
Participants were randomised 6:1 to several weekly cagrilintide levels, liraglutide 3.0 mg daily or volume-matched placebo, across a 26-week treatment period that included up to 6 weeks of escalation.[2]
The primary endpoint was the percentage change in bodyweight from baseline to week 26, analysed under two different estimands.[2]
Weight and tolerability results reported for cagrilintide
On the trial-product estimand, mean weight reductions with cagrilintide 0.3-4.5 mg ranged from 6.0% to 10.8%, against 3.0% with placebo.[2]
Cagrilintide 4.5 mg produced a larger reduction than liraglutide 3.0 mg (10.8% against 9.0%, p=0.03).[2]
Permanent discontinuation occurred in 73 participants (10%), mostly because of adverse events (30 participants, 4%).[2]
Gastrointestinal adverse events affected 41%-63% of cagrilintide recipients against 32% on placebo, with nausea at 20%-47% against 18%.[2]
Sources
- 1Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
Found an error? Report a correction.